Journal
ACS NANO
Volume 16, Issue 2, Pages 2330-2344Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.1c08538
Keywords
urease; micromotor; nanodrugs; neutrophil extracellular traps; thrombosis
Categories
Funding
- Xiamen Medical and Health Guidance Project [3502Z20209144]
- Xiamen Cardiovascular Hospital of Xiamen University
Ask authors/readers for more resources
This study reports the use of a urease-driven NEs nanodrug delivery system to promote thrombolysis and inhibit rethrombosis. The system actively targets thrombi and releases nanoparticles to induce thrombolysis, with high bioavailability and biosafety. It provides a potential treatment for thrombotic diseases.
Utilizing neutrophils (NEs) to target and deliver nanodrugs to inflammation sites has received considerable attention. NEs are involved in the formation and development of thrombosis by transforming into neutrophil extracellular traps (NETs); this indicates that NEs may be a natural thrombolytic drug delivery carrier. However, NEs lack an effective power system to overcome blood flow resistance and enhance targeting efficiency. Herein, we report the application of a urease catalysis micromotor powered NEs nanodrug delivery system to promote thrombolysis and suppress rethrombosis. The urease micromotor powered Janus NEs (UM-NEs) were prepared by immobilizing the enzyme asymmetrically onto the surface of natural NEs and then loading urokinase (UK) coupled silver (Ag) nanoparticles (Ag-UK) to obtain the UM-NEs (Ag-UK) system. Urease catalytic endogenous urea is used to generate thrust by producing ammonia and carbon dioxide, which propels NEs actively targeting the thrombus. The UM-NEs (Ag-UK) can be activated by enriched inflammatory cytokines to release NETs at the thrombosis site, resulting in a concomitant release of Ag-UK. Ag-UK induces thrombolysis to restore vascular recanalization. This urease micromotor-driven NEs drug delivery system can significantly reduce the hemorrhagic side effects, promote thrombolysis, and inhibit rethrombosis with high bioavailability and biosafety, which can be used for the treatment of thrombotic diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available